STRA8: A Potential Drug Target and Biomarker (G346673)

Target Name: STRA8

NCBI ID: G346673

STRA8

STRA8: A Potential Drug Target and Biomarker

STRA8, also known as retinoic acid gene 8 homolog, is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and its potential as a therapeutic target have made it an attractive focus for researchers in the field of biotechnology and medicine.

The STRA8 gene is located on chromosome 18q21 and encodes a protein known as STRA8, which is a key regulator of the retinoblastoma gene (RB). Retinoblastoma is a type of cancer that affects the eye, and it is characterized by the rapid and uncontrolled growth of cells that can lead to blindness or other serious health problems.

Research has shown that STRA8 plays a critical role in the development and progression of RB, and that it is often expressed at higher levels in individuals with RB than in those without the disease. Additionally, studies have suggested that STRA8 may be involved in the regulation of cell growth and differentiation, and that it may be a potential therapeutic target for RB and other diseases.

One of the key reasons for the interest in STRA8 is its potential as a drug target. The development of drug-resistant cancer has become a major challenge in the field of medicine, and researchers are always looking for new and effective ways to treat these diseases. STRA8 has the potential to be a valuable drug target because it is involved in the regulation of cell growth and differentiation, which are critical processes that are often disrupted in cancer cells.

In addition to its potential as a drug target, STRA8 has also been identified as a potential biomarker for several diseases, including RB, cancer, and neurodegenerative disorders. The use of STRA8 as a biomarker could help doctors to diagnose and monitor these diseases more accurately, and could also be used to identify potential new treatments.

Research has shown that STRA8 is expressed in a variety of tissues and cells, including eye cells, brain cells, and cancer cells. It is also shown to be involved in the regulation of cell growth, differentiation, and survival. These properties make it an attractive candidate as a biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and RB.

Another promising aspect of STRA8 is its location on chromosome 18q21, which makes it a potential candidate for genetic modifiers. Several studies have shown that STRA8 is highly conserved across different species, and that it is located in a region of the genome that is commonly targeted by genetic modifiers. This suggests that STRA8 may be a good candidate for genetic modifiers, which could potentially improve its therapeutic effectiveness.

In conclusion, STRA8 is a gene that has shown promise as a potential drug target and biomarker for a variety of diseases. Its unique function and its potential as a therapeutic target, as well as its potential as a biomarker, make it an attractive focus for researchers in the field of biotechnology and medicine. Further studies are needed to fully understand its potential and to develop effective treatments for the diseases it is involved in.

Protein Name: Stimulated By Retinoic Acid 8

Functions: Meiosis-inducer required for the transition into meiosis for both female and male germ cells. In female germ cells, acts downstream of ZGLP1 as a key effector of the meiotic program: required for premeiotic DNA replication and subsequent events in meiotic prophase. During spermatogenesis, next to its role in meiotic initiation, promotes (but is not required for) spermatogonial differentiation. In complex with MEIOSIN, directly activates the transcription of a subset of critical meiotic genes playing a central role in cell-cycle switching from mitosis to meiosis

The "STRA8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STRA8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets